BR112017009764A2 - anticorpos biespecíficos e métodos de uso em oftalmologia - Google Patents

anticorpos biespecíficos e métodos de uso em oftalmologia

Info

Publication number
BR112017009764A2
BR112017009764A2 BR112017009764A BR112017009764A BR112017009764A2 BR 112017009764 A2 BR112017009764 A2 BR 112017009764A2 BR 112017009764 A BR112017009764 A BR 112017009764A BR 112017009764 A BR112017009764 A BR 112017009764A BR 112017009764 A2 BR112017009764 A2 BR 112017009764A2
Authority
BR
Brazil
Prior art keywords
bispecific antibodies
ophthalmology
methods
human
1beta
Prior art date
Application number
BR112017009764A
Other languages
English (en)
Portuguese (pt)
Inventor
Weiser Barbara
Gassner Christian
Hartmann Guido
Georges Guy
Kettenberger Hubert
Moelleken Joerg
Thomas Regula Joerg
Bedoucha Marc
Molhoj Michael
Mundigl Olaf
Michael Huelsmann Peter
Schumacher Ralf
Gruener Sabine
Breuer Sebastian
Dengl Stefan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112017009764A2 publication Critical patent/BR112017009764A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112017009764A 2014-11-10 2015-11-06 anticorpos biespecíficos e métodos de uso em oftalmologia BR112017009764A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14192517 2014-11-10
PCT/EP2015/075879 WO2016075037A1 (en) 2014-11-10 2015-11-06 Bispecific antibodies and methods of use in ophthalmology

Publications (1)

Publication Number Publication Date
BR112017009764A2 true BR112017009764A2 (pt) 2018-02-20

Family

ID=51868112

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017009764A BR112017009764A2 (pt) 2014-11-10 2015-11-06 anticorpos biespecíficos e métodos de uso em oftalmologia

Country Status (15)

Country Link
US (1) US10730938B2 (cg-RX-API-DMAC10.html)
EP (1) EP3218399A1 (cg-RX-API-DMAC10.html)
JP (1) JP2017537896A (cg-RX-API-DMAC10.html)
KR (1) KR20170080584A (cg-RX-API-DMAC10.html)
CN (1) CN107074941A (cg-RX-API-DMAC10.html)
AR (1) AR102592A1 (cg-RX-API-DMAC10.html)
AU (1) AU2015345323A1 (cg-RX-API-DMAC10.html)
BR (1) BR112017009764A2 (cg-RX-API-DMAC10.html)
CA (1) CA2963175A1 (cg-RX-API-DMAC10.html)
IL (1) IL251128A0 (cg-RX-API-DMAC10.html)
MX (1) MX2017005977A (cg-RX-API-DMAC10.html)
RU (1) RU2017120360A (cg-RX-API-DMAC10.html)
SG (1) SG11201703428SA (cg-RX-API-DMAC10.html)
TW (1) TW201632551A (cg-RX-API-DMAC10.html)
WO (1) WO2016075037A1 (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2417156E (pt) 2009-04-07 2015-04-29 Roche Glycart Ag Anticorpos trivalentes, biespecíficos
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
WO2016075035A1 (en) * 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag Anti-ang2 antibodies and methods of use
SG11201702550WA (en) 2014-11-10 2017-04-27 Hoffmann La Roche ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
JP2017537896A (ja) 2014-11-10 2017-12-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二重特異性抗体及び眼科に使用する方法
EP3218400A1 (en) 2014-11-10 2017-09-20 F. Hoffmann-La Roche AG Anti-pdgf-b antibodies and methods of use
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
CN109863171B (zh) 2016-08-23 2023-08-04 免疫医疗有限公司 抗vegf-a和抗ang2抗体及其用途
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
WO2020127873A1 (en) * 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Antibody that binds to vegf and il-1beta and methods of use
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
JP7674383B2 (ja) * 2020-03-30 2025-05-09 エフ． ホフマン－ラ ロシュ アーゲー Ｖｅｇｆ及びｐｄｇｆ－ｂに結合する抗体及び使用方法
JP2024520693A (ja) * 2021-06-04 2024-05-24 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド ＶＥＧＦとＡｎｇ２に結合する二重特異性結合分子およびその使用
CN116925234B (zh) * 2022-04-02 2024-05-31 合肥星眸生物科技有限公司 一种编码抗vegf-a和ang-2双特异性抗体的aav载体
CN117467025B (zh) * 2023-12-28 2024-04-16 上海鼎新基因科技有限公司 一种抗vegf和补体双功能融合蛋白及其应用
WO2025211874A1 (ko) * 2024-04-04 2025-10-09 주식회사 크로스포인트테라퓨틱스 인간 항체 fc 변이체 포함 이중항체 및 그 용도

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935343A (en) 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AU2003208946A1 (en) 2002-02-28 2003-09-16 Eli Lilly And Company Anti-interleukin-1 beta analogs
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
JP4538461B2 (ja) 2003-01-24 2010-09-08 アプライド モレキュラー エボリューション，インコーポレイテッド ヒトＩＬ−１βアンタゴニスト
RU2346950C2 (ru) 2003-01-28 2009-02-20 Академис Зикенхейс Лейден Пептидные ингибиторы токсинов, производные ll-37
WO2005052002A2 (en) 2003-11-20 2005-06-09 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
US20050282233A1 (en) * 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
ZA200705695B (en) 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
BRPI0811466A2 (pt) 2007-05-07 2014-10-14 Medimmune Llc Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica.
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8293714B2 (en) 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
HRP20130042T1 (hr) 2008-06-06 2013-03-31 Xoma Technology Ltd. Postupci lijeäśenja reumatoidnog artritisa
RU2368359C1 (ru) 2008-07-22 2009-09-27 Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) Способ лечения возрастной макулярной дегенерации
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
NZ593905A (en) 2009-01-29 2013-03-28 Abbott Lab Il-1 binding proteins
AU2010306681A1 (en) 2009-10-15 2012-04-19 Abbvie Inc. IL-1 binding proteins
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
BR112012028557A2 (pt) * 2010-05-07 2019-09-24 Xoma Technology Ltd. uso de um anticorpo anti-il-1b ou de fragmentos de ligação do mesmo.
CN104474546A (zh) 2010-08-13 2015-04-01 弗·哈夫曼-拉罗切有限公司 用于疾病治疗的针对IL-1β和IL-18的抗体
WO2012034039A2 (en) 2010-09-10 2012-03-15 Apexigen, Inc. Anti-il-1 beta antibodies and methods of use
MX2013007332A (es) 2010-12-21 2014-01-23 Abbvie Inc Inmunoglobulinas de dominio variable doble biespecificas de il-1 alfa y beta y su uso.
WO2012125850A1 (en) 2011-03-16 2012-09-20 Amgen Inc. Fc variants
EP2726088B1 (en) 2011-06-29 2019-01-02 Amgen Inc. Predictive biomarker of survival in the treatment of renal cell carcinoma
SG11201408196RA (en) * 2012-06-28 2015-03-30 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
SI3495387T1 (sl) * 2012-07-13 2021-12-31 Roche Glycart Ag Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
US20140093498A1 (en) 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents
WO2014049100A1 (en) 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents
AU2013342275B2 (en) 2012-11-08 2017-11-09 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
RU2015115956A (ru) * 2012-11-09 2017-01-10 Пфайзер Инк. Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
AU2014227732A1 (en) 2013-03-15 2015-09-17 Abbvie Inc. Dual specific binding proteins directed against IL-1 beta and IL-17
CA2904806C (en) * 2013-04-29 2021-11-23 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
CN105611944A (zh) 2013-12-20 2016-05-25 豪夫迈·罗氏有限公司 抗ang2抗体和cd40激动剂的组合疗法
CN110903398B (zh) 2014-01-15 2023-08-15 豪夫迈·罗氏有限公司 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
UA117289C2 (uk) * 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
JP2017537896A (ja) 2014-11-10 2017-12-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二重特異性抗体及び眼科に使用する方法
EP3218400A1 (en) 2014-11-10 2017-09-20 F. Hoffmann-La Roche AG Anti-pdgf-b antibodies and methods of use
WO2016075035A1 (en) 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag Anti-ang2 antibodies and methods of use
SG11201702550WA (en) 2014-11-10 2017-04-27 Hoffmann La Roche ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
WO2016209972A1 (en) 2015-06-26 2016-12-29 Amgen Inc. Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor
BR112019022074A2 (pt) 2017-06-02 2020-05-12 Boehringer Ingelheim International Gmbh Terapia de combinação anticâncer

Also Published As

Publication number Publication date
KR20170080584A (ko) 2017-07-10
US10730938B2 (en) 2020-08-04
JP2017537896A (ja) 2017-12-21
WO2016075037A1 (en) 2016-05-19
CN107074941A (zh) 2017-08-18
SG11201703428SA (en) 2017-05-30
EP3218399A1 (en) 2017-09-20
AU2015345323A1 (en) 2017-04-06
US20170240629A1 (en) 2017-08-24
AR102592A1 (es) 2017-03-08
TW201632551A (zh) 2016-09-16
IL251128A0 (en) 2017-04-30
RU2017120360A3 (cg-RX-API-DMAC10.html) 2019-10-18
CA2963175A1 (en) 2016-05-19
RU2017120360A (ru) 2018-12-13
MX2017005977A (es) 2017-06-29

Similar Documents

Publication Publication Date Title
MX2017005977A (es) Anticuerpos biespecificos y metodos de uso en oftalmologia.
JOP20200192A1 (ar) أجسام مضادة لـ tigit
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
CY1122804T1 (el) Μονοκλωνικα αντισωματα εναντι ανθρωπινου αντιγονου ωριμανσης β κυτταρων (βcμα)
CY1121893T1 (el) Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων
EA201791093A1 (ru) Антитела к cd47, способы и применение
BR112017001579A2 (pt) anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
SA518400222B1 (ar) أجسام مضادة لـ وتركيبات tim-3
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201790248A1 (ru) Композиции носитель-антитело и способы их получения и применения
MX388350B (es) Anticuerpos anti-cd166, anticuerpos anti-cd166 activables, y metodos de uso de los mismos.
IL271260A (en) Multi-specific antibodies and methods of making and using thereof
DOP2017000083A (es) Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos
IL247221B (en) Antibodies binding dengue virus, compositions comprising same and uses thereof
CU20160101A7 (es) Inmunoglobulina con fab en tándem
EA201691991A1 (ru) Мультиспецифические антитела
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
IL271257A (en) Multi-specific antibodies and methods of making and using thereof
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
IL246837B (en) Antibodies, pharmaceutical compositions and uses thereof
MX2016005956A (es) Anticuerpos especificos para fcrn.
MX2017011194A (es) Anticuerpos, usos y métodos.
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]